STING-V1 Citations (4)
Originally described in: Schirmer lab plasmidsUnpublished
Articles Citing STING-V1
| Articles |
|---|
| ER-lysosome lipid transfer protein VPS13C/PARK23 prevents aberrant mtDNA-dependent STING signaling. Hancock-Cerutti W, Wu Z, Xu P, Yadavalli N, Leonzino M, Tharkeshwar AK, Ferguson SM, Shadel GS, De Camilli P. J Cell Biol. 2022 Jul 4;221(7):e202106046. doi: 10.1083/jcb.202106046. Epub 2022 Jun 3. PubMed |
| cGAMP-adjuvanted multivalent influenza mRNA vaccines induce broadly protective immunity through cutaneous vaccination in mice. Zhu W, Wei L, Dong C, Wang Y, Kim J, Ma Y, Gonzalez GX, Wang BZ. Mol Ther Nucleic Acids. 2022 Nov 9;30:421-437. doi: 10.1016/j.omtn.2022.10.024. eCollection 2022 Dec 13. PubMed |
Optogenetic engineering of STING signaling allows remote immunomodulation to enhance cancer immunotherapy.
Dou Y, Chen R, Liu S, Lee YT, Jing J, Liu X, Ke Y, Wang R, Zhou Y, Huang Y.
Nat Commun. 2023 Sep 6;14(1):5461. doi: 10.1038/s41467-023-41164-2.
PubMed
Associated Plasmids |
| Oncolytic peptide LTX-315 plus an anti-CTLA-4 antibody induces a synergistic anti-cancer immune response in residual tumors after radiofrequency ablation of hepatocellular carcinoma. Sun B, Liu J, Liu X, Li J, Zhang G, Sun T, Zheng C, Kan X. Cell Death Dis. 2025 Apr 13;16(1):288. doi: 10.1038/s41419-025-07622-z. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.